CD274 and neoplasm: Treatment with the EGFR inhibitor erlotinib also led to decreased PD-L1 expression in tumor cell lines that harbor mutant EGFR but not in cells that have wild-type EGFR, further supporting the link between activated EGFR signaling and PD-L1 expression (82).